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A BS TR AC T
BACKGROUND
Options for mechanical circulatory support as a bridge to heart transplantation in 
children with severe heart failure are limited.
METHODS
We conducted a prospective, single-group trial of a ventricular assist device designed 
specifically for children as a bridge to heart transplantation. Patients 16 years of age 
or younger were divided into two cohorts according to body-surface area (cohort 1, 
<0.7 m2; cohort 2, 0.7 to <1.5 m2), with 24 patients in each group. Survival in the 
two cohorts receiving mechanical support (with data censored at the time of trans-
plantation or weaning from the device owing to recovery) was compared with survival 
in two propensity-score–matched historical control groups (one for each cohort) 
undergoing extracorporeal membrane oxygenation (ECMO).
RESULTS
For participants in cohort 1, the median survival time had not been reached at 174 days, 
whereas in the matched ECMO group, the median survival was 13 days (P<0.001 by the 
log-rank test). For participants in cohort 2 and the matched ECMO group, the median 
survival was 144 days and 10 days, respectively (P<0.001 by the log-rank test). Serious 
adverse events in cohort 1 and cohort 2 included major bleeding (in 42% and 50% 
of patients, respectively), infection (in 63% and 50%), and stroke (in 29% and 29%).
CONCLUSIONS
Our trial showed that survival rates were significantly higher with the ventricular 
assist device than with ECMO. Serious adverse events, including infection, stroke, 
and bleeding, occurred in a majority of study participants. (Funded by Berlin Heart 
and the Food and Drug Administration Office of Orphan Product Development; 
ClinicalTrials.gov number, NCT00583661.)
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Systolic heart failure causes 280,000 deaths in adults annually in the United States.1 Heart failure is much less common 
among children than among adults, but it is high-
ly lethal, with 46% of children with heart failure 
dying or undergoing transplantation within 5 years 
after diagnosis, according to one estimate.2 The 
survival rate among children after heart transplan-
tation is estimated at 83% at 3 years,3,4 but the 
limited availability of donor hearts for children 
prolongs the waiting period,5 resulting in a high 
rate of death among children on waiting lists.6-8
Options for mechanical circulatory support as 
a bridge to transplantation are limited for chil-
dren. The mainstay of support for small children 
has been extracorporeal membrane oxygenation 
(ECMO). The effective period of support with 
ECMO is typically limited to only 10 to 20 days 
before serious complications ensue, such as bleed-
ing and major organ-system failure, which often 
preclude transplantation. The short duration of 
support afforded by ECMO is often inadequate, 
considering the current waiting times (a median 
of 119 days for all infants in 20085). As a result, 
only 40 to 60% of children requiring support with 
ECMO survive long enough to undergo heart trans-
plantation.9
The Excor Pediatric ventricular assist device 
(Berlin Heart) is a paracorporeal, pneumatically 
driven, pulsatile-flow mechanical circulatory-
support device available in a wide range of sizes. 
We conducted a prospective study to evaluate this 
device as bridge therapy in children who were on 
waiting lists for orthotopic heart transplantation.
ME THODS
STUDY DESIGN
In this prospective, multicenter, single-group co-
hort study,10 we compared children who underwent 
implantation of the Excor Pediatric ventricular 
assist device as a bridge to transplantation with a 
historical control group of children who received 
circulatory support with ECMO. Seventeen pediat-
ric cardiac centers in the United States and Canada 
participated in the trial (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org, for a list of study sites and in-
vestigators).
The study was designed by the principal inves-
tigators and by clinical experts in pediatric trial 
design, hematology, and neurology in collabora-
tion with the sponsor, Berlin Heart, and the Food 
and Drug Administration. Data were gathered by 
study coordinators at each site and were analyzed 
by the sponsor and independent academic statisti-
cians in collaboration with the study investigators. 
The investigators had full access to the data. Data 
monitoring was performed by a contract research 
organization (Alquest). Data confidentiality was 
required by contractual agreement between each 
study site and the sponsor. The decision to submit 
the manuscript for publication was made by mem-
bers of the publication committee (see the Supple-
mentary Appendix) and the sponsor. All authors 
participated in writing, revising, and reviewing the 
manuscript. The academic authors and the authors 
who are employees of the sponsor vouch for the 
accuracy and completeness of the data and analy-
sis and the fidelity of the study to the trial pro-
tocol. The study protocol (available at NEJM.org) 
was approved by the institutional review board at 
each participating center, and written informed 
consent was provided by a parent or legal guard-
ian for all study participants.
PARTICIPANT SELECTION
Children were eligible for the study if they were 
16 years of age or younger, weighed between 3 and 
60 kg, had two-ventricle circulation, had severe 
heart failure despite optimized medical treatment, 
and were on a waiting list for cardiac transplan-
tation. Children who had already been receiving 
another form of mechanical circulatory support 
were allowed to participate, except for those who 
had received circulatory support with ECMO for 
10 days or more (see Table S1 in the Supplemen-
tary Appendix for a complete list of inclusion and 
exclusion criteria). After enrollment, participants 
were stratified according to body-surface area. 
Cohort 1 included all participants with a body-
surface area of less than 0.7 m2, and cohort 2 all 
participants with a body-surface area of at least 
0.7 m2 but less than 1.5 m2.
STUDY PROTOCOL
Each participant underwent surgical implantation 
of an Excor Pediatric ventricular assist device, the 
size of which was chosen on the basis of age 
and body weight. Devices with stroke volumes of 
10, 25, 30, 50, and 60 ml were available (Fig. S1 
and S2 in the Supplementary Appendix).11 Par-
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ticipants underwent implantation of one device 
in the left ventricle only (left ventricular assist) or 
of devices in both left and right ventricles (biven-
tricular assist) on the basis of an algorithm de-
veloped to predict right-heart performance at the 
time of surgery and at the clinical discretion of the 
surgeon performing the implantation.10 Standard-
ized antithrombotic therapy was recommended 
(Fig. S3 in the Supplementary Appendix).10 After 
postoperative recovery, patients in stable condi-
tion were typically treated with aspirin, dipyrid-
amole, and either warfarin or enoxaparin.
Study data were collected within 48 hours 
before device implantation; at implantation; at 1, 
2, 4, and 6 weeks; at 3 and 6 months; and every 
3 months thereafter while the child received cir-
culatory support with the ventricular assist device. 
Participants who were deemed to be acceptable 
candidates for a heart transplant after implanta-
tion of the device underwent transplantation if 
and when a suitable donor organ became avail-
able. Participants with signs of substantial ven-
tricular recovery were weaned from the ventricu-
lar assist device, meaning that support with the 
device was gradually discontinued, and the pump 
surgically explanted.
SELECTION OF HISTORICAL CONTROL GROUP
A historical control group of children receiving cir-
culatory support with ECMO was selected from the 
Extracorporeal Life Support Organization (ELSO) 
registry. The ELSO registry is a multicenter, vol-





Group for  
Cohort 1




Group for  
Cohort 2
(N = 48)† P Value‡
Age — mo§
Median 11.7 10.6 0.53 111.2 138.7 0.96
Range 2.6–45.6 0.1–112.3 50.8–191.8 1.8–188.6
Weight — kg§
Median 9.2 8.8 0.79 30.7 36.0 0.96
Range 3.6–13.6 3.1–27.0 16.0–58.1 4.0–59.0
Primary diagnosis — no. (%)§ 0.32 0.51
Congenital heart disease 3 (12) 8 (17) 6 (25) 15 (31)
Coronary artery disease 0 0 0 1 (2)
Dilated cardiomyopathy or myocarditis 19 (79) 39 (81) 17 (71) 31 (65)
Hypertrophic cardiomyopathy 1 (4) 0 0 0
Restrictive cardiomyopathy 1 (4) 0 1 (4) 0
Valvular heart disease 0 1 (2) 0 1 (2)
Preoperative mechanical ventilation — no. (%)§ 20 (83) 36 (75) 0.42 11 (46) 26 (54) 0.50
Preoperative inotrope infusion — no. (%)§ 22 (92) 43 (90) 0.78 21 (88) 40 (83) 0.64
Preoperative cardiac arrest — no. (%)§ 7 (29) 14 (29) 1.00 5 (21) 13 (27) 0.56
Body-surface area — m2
Median 0.44 1.08
Range 0.23–0.62 0.71–1.66‖
Male sex — no. (%) 12 (50) 13 (54)
INTERMACS profile status at implantation —  
no. (%)¶
1 11 (46) 13 (54)
2 13 (54) 11 (46)
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untary database that enrolls patients who receive 
ECMO support. A propensity-score analysis was 
used to match each participant who received a 
ventricular assist device to two children who had 
received support with ECMO (selected from the 
ELSO database). The propensity-score matching 
was performed separately and independently for 
each of the two cohorts. Details regarding the 
ELSO database and the propensity-score match-
ing are provided in the Supplementary Appendix.
STUDY OUTCOMES
The primary efficacy end point was defined differ-
ently for the ventricular-assist and ECMO groups. 
For the ventricular-assist group, the primary end 
point was the time to death or weaning from the 
device with an unacceptable neurologic outcome. 
Death was defined as any death occurring while 
the child required support with the device or death 
within 30 days after weaning from the device or 
before hospital discharge, whichever was longer. 
An unacceptable neurologic outcome was defined 
as either coma or the presence of profound sensory, 
motor, language, or cognitive impairment as as-
sessed with the Pediatric Stroke Outcome Mea-
sure12 (see the Supplementary Appendix for details 
of the neurologic assessments and the Pediatric 
Stroke Outcome Measure). Data from participants 
who underwent heart transplantation or who had 
ventricular recovery with uneventful weaning from 
the device were censored at the time of trans-
plantation or weaning.
For the ECMO group, the primary end point 
was only the time to death (as defined above), 
because data on neurologic status were not avail-
able in the ELSO database. Data from patients who 
underwent device explantation and survived for at 
least 30 days were censored; the ELSO database 
does not specify whether such explants were due 
to recovery or transplantation.
In a secondary outcome assessment, outcome 
events were classified for a competing-risk analy-
sis. For the ventricular-assist group, four mutually 
exclusive outcome events were tracked: death dur-
ing receipt of circulatory support with the device; 






Group for  
Cohort 1




Group for  
Cohort 2
(N = 48)† P Value‡
Preoperative ECMO — no. (%) 6 (25) 8 (33)
Preoperative centrifugal VAD — no. (%) 2 (8) 0
Type of implant — no. (%)
LVAD 17 (71) 14 (58)
BiVAD 7 (29) 10 (42)
Closure of intracardiac shunt at implantation  
— no. (%)
7 (29) 3 (12)
Valve repair or replacement at implantation  
— no. (%)
2 (8) 4 (17)
Time required for cardiopulmonary bypass  
— min
185±49 176±52
* Plus–minus values are means ±SD. BiVAD denotes biventricular assist device, ECMO extracorporeal membrane oxygenation, LVAD left ven-
tricular assist device, and VAD ventricular assist device.
† The correlation coefficient for the matched propensity scores was 0.97 for cohort 1 (P<0.001) and 0.96 for cohort 2 (P<0.001).
‡ P values for comparison of the ventricular-assist cohorts with the propensity-score–matched ECMO groups were obtained with the t-test or 
chi-square test.
§ These variables were used in the propensity-score analysis to match historical control groups from the Extracorporeal Life Support Organization 
(ELSO) database with the ventricular-assist cohorts.
¶ According to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS),13 a profile status of 1 indicates critical 
cardiogenic shock, and 2 progressive decline.
‖ One participant had a body-surface area of 1.66 m2, which was outside the eligibility-criteria specifications; a protocol deviation was docu-
mented for this occurrence.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 26, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;6 nejm.org august 9, 2012536
as death or an unacceptable neurologic outcome, 
as defined above, within 30 days after weaning or 
before discharge from the hospital, whichever was 
longer); and successful weaning (defined as wean-
ing from the device without death or an unac-
ceptable neurologic outcome within 30 days after 
weaning or before discharge from the hospital). 
For the ECMO group, three mutually exclusive out-
come events were tracked: death during receipt of 
support with ECMO, death within 30 days after 
weaning from the device, and removal of the de-
vice (without death within 30 days after device re-
moval). For both groups, children who had not yet 
had any of these specific outcome events were clas-
sified as being alive and receiving support with the 
device.
Additional data were collected for the ventric-
ular-assist group. Data on device performance 
(e.g., function of the driver system and the drive 
lines, system failures, systolic and diastolic pres-
sures, and stroke rate) were recorded routinely 
while participants receiving circulatory support 
with the device. Functional status was assessed at 
each time point by determining whether the par-
ticipant was sedated, intubated, eating, or ambu-
lating. Information about functional status is pro-
vided in the Supplementary Appendix. Adverse 
events were documented throughout the study 
according to standardized definitions from the 
Interagency Registry for Mechanically Assisted 
Circulatory Support13 (Table S3 in the Supplemen-
tary Appendix).
A clinical events committee adjudicated all ad-
verse events, the neurologic status of patients 
who were considered to be weaned from the de-
vice owing to recovery, and deaths. A data and 
safety monitoring committee evaluated the study 
data every 6 months to ensure the safety of the 
participants and the integrity of the study (see 
the Supplementary Appendix).
STATISTICAL ANALYSIS
We estimated that the median time to the primary 
end point for participants with the ventricular assist 
device would be 100 days, and the median time to 
the primary end point for the propensity-score–
matched control group of children receiving sup-
port with ECMO would be 5 days. On the basis of 
these assumptions, we calculated that the inclusion 
of 24 participants in each ventricular-assist cohort 
would provide more than 99% power, with a two-
sided alpha level of 0.05, to test the hypothesis that 
survival with the ventricular assist device would be 
significantly longer than survival with ECMO.
All comparisons between the ventricular-assist 
and ECMO groups were performed on an inten-
tion-to-treat basis. Cumulative event rates were 
calculated according to the Kaplan–Meier method. 
For the ventricular-assist group, the time to an 
event was measured from the time of implantation 
of the ventricular assist device, regardless of 
whether another form of mechanical support had 
been in use before implantation. For the ECMO 
group, the time to an event was measured from 
the time of implantation of the ECMO device. The 
between-group difference in the time to the oc-
currence of the primary end point was assessed 
by means of the log-rank test within each of the 
two study cohorts. The duration of support with 
the device was compared with the use of the 
Wilcoxon median two-sample test.
The primary efficacy outcome was also evalu-
ated with the use of a competing-risk analysis. The 
proportion of participants having each of the com-
peting outcomes at each time point was plotted. 
Outcomes at 30 days and at the end of device sup-
port for the participant who received support for 
the longest time were compared between groups 
with the use of chi-square tests.
The primary safety end point was calculated as 
the number of serious adverse events per day dur-
ing circulatory support with the ventricular assist 
device. A Poisson exact confidence interval was 
calculated, and the critical-value method was used 
for significance testing. Success was prospectively 
defined as less than 0.25 events per day for the 
upper bound of the 95% Poisson exact confidence 
interval. A two-tailed Fisher’s exact test was used 
to compare the proportion of participants in each 
functional-status category at each time point with 
the proportion in each category before the devices 
were implanted.
All reported P values are two-sided. A P value of 
less than 0.05 was considered to indicate statisti-




We enrolled 48 children, 24 in each cohort, in the 
trial between May 2007 and December 2010. In 
cohort 1, the median age was 1 year and the me-
dian weight was 9 kg. In cohort 2, the median age 
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was 9 years and the median weight was 31 kg. In 
both cohorts, the cause of cardiac failure in most 
participants was cardiomyopathy or myocarditis, 
with a much smaller proportion having congeni-
tal heart disease (Table 1). The propensity-score–
matching process resulted in statistically well-
matched control groups (Table 1, and Table S2 in 
the Supplementary Appendix).
DEVICE EFFICACY AND SUPPORT OUTCOMES
For children in cohort 1, the median duration of 
support with the ventricular assist device was 
28 days, as compared with 5 days for the matched 
ECMO group (P<0.001 by the Wilcoxon median 
two-sample test). The longest duration of sup-
port with the device in each of these two groups 
was 174 days and 21 days, respectively. For chil-
dren in cohort 2, the median duration of support 
with the device was 43 days, as compared with 
5 days for the matched ECMO group (P<0.001 by 
the Wilcoxon median two-sample test). The lon-
gest duration of support with the device in each 
of these two groups was 192 days and 28 days, 
respectively.
Among participants in cohort 1, the median 
time to the primary end point had not yet been 
reached at 174 days. In contrast, the median time 
to the primary end point in the matched ECMO 
group was 13 days (P<0.001 by the log-rank test) 
(Fig. 1A). Among participants in cohort 2, the me-
dian time to the primary end point was 144 days, 
as compared with 10 days in the matched ECMO 
group (P<0.001 by the log-rank test) (Fig. 1B).
Competing-outcome analyses are shown in 
Figures 2 and 3. In the ECMO group for cohort 
1, at 21 days, 25% of the patients had died, and 
none were alive and still receiving support with 
ECMO (Fig. 2A). In the ECMO group for cohort 
2, at 30 days, 33% of the patients had died, and 
none were alive and still receiving support 
with ECMO (Fig. 2B). In contrast, in cohort 1, at 
174 days, 88% of the patients had undergone 
successful transplantation and 12% had died or 
had an unacceptable neurologic outcome after 
weaning from the device (Fig. 3A). In cohort 2, 
at 192 days, 92% of the patients had undergone 
successful transplantation or had been weaned 
from the device, and 8% had died (Fig. 3B). 
Overall, 88% of the participants in cohort 1 and 
92% of those in cohort 2 survived to undergo 
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Figure 1. Kaplan–Meier Estimates of Freedom from the Primary End Point 
for Patients Who Received a Ventricular Assist Device and for Matched 
Control Groups of Children Who Received Support with Extracorporeal 
Membrane Oxygenation (ECMO).
Panels A and B show the data from cohorts 1 and 2, respectively, as compared 
with data from their propensity-score–matched control groups. For both ven-
tricular-assist cohorts, the primary end point was the time to death or weaning 
from the device with an unacceptable neurologic outcome. Death was defined 
as any death occurring while the child required support with the device, or any 
death occurring within 30 days after weaning from the device or before dis-
charge from the hospital, whichever was longer. An unacceptable neurologic 
outcome was defined as either coma or the presence of profound sensory, mo-
tor, language, or cognitive impairment as assessed with the Pediatric Stroke 
Outcome Measure12 (see the Supplementary Appendix). Data from partici-
pants who underwent heart transplantation or who had ventricular recovery 
with uneventful weaning were censored at the time of transplantation or wean-
ing. For the ECMO groups, the primary end point was only the time to death 
(as defined above), because data on neurologic status were not available in the 
Extracorporeal Life Support Organization (ELSO) database. Data from patients 
who underwent device explantation and survived for at least 30 days were cen-
sored; the ELSO database does not specify whether such explants were per-
formed because of recovery or transplantation. Each tick mark represents an 
event, and I bars indicate asymmetric confidence intervals equivalent to 1 SE.
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ADVERSE EVENTS
The rate of serious adverse events in cohort 1 was 
0.07 events per patient-day (95% confidence in-
terval [CI], 0.06 to 0.08), and in cohort 2, the rate 
was 0.08 events per patient-day (95% CI, 0.06 to 
0.09). The upper bounds of the 95% confidence 
intervals were both below the prospectively set 
criterion for success of 0.25.
The most common serious adverse events 
were major bleeding (in 42% of participants in 
cohort 1 and in 50% of those in cohort 2), infec-
tion (in 63% and 50%, respectively), stroke (in 
29% and 29%), and hypertension (in 50% and 
33%). More details regarding deaths and adverse 
neurologic outcomes, as well as a table of 
 adverse events (Table S7 in the Supplementary 
Appendix), are provided in the Supplementary Ap-
pendix.
Forty-six pump changes occurred in cohorts 
1 and 2 combined. Thrombus formation in the 
device was identified as the reason for 43 of 
these pump changes. Pump changes were re-
quired in three participants for whom no throm-
bus in the device was identified: one participant 
had multiple infarcts on computed tomography 
of the head, one had a neurologic event, and one 
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Figure 2. Competing-Outcomes Analysis of the ECMO 
Groups.
Three mutually exclusive outcome events were tracked 
for this analysis: death occurring while the child was 
receiving circulatory support with ECMO, death within 
30 days after weaning from the device, and device removal 
(without death within 30 days). Children who had not 
yet had any of these specific outcome events were clas-
sified as being alive and receiving circulatory support.
Figure 3. Competing-Outcomes Analysis of the Ventricular-
Assist Cohorts.
Four mutually exclusive outcome events were tracked for 
this analysis: death occurring while the child was receiv-
ing circulatory support with the ventricular assist device, 
heart transplantation, weaning from the device but either 
dying or having an unacceptable neurologic outcome 
within 30 days after weaning or before discharge from the 
hospital (whichever was longer), and weaning from the 
device without death or an unacceptable neurologic out-
come in the period defined above. Children who had not 
yet had any of these specific outcome events were classi-
fied as being alive and receiving circulatory support.
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DISCUSSION
Adults with severe heart failure have benefited 
from a series of technological advances in the 
use of ventricular assist devices as a bridge to 
heart transplantation.14-16 Progress in developing 
pediatric devices has been much slower because 
of the proportionately greater variation in size 
among children. Other reasons for the slow 
progress include biologic differences in the re-
sponse to anticoagulant medicines, low levels of 
interest in the medical industry, and in particu-
lar, the size constraints in very small babies.
In this trial, we evaluated the use of the Excor 
Pediatric ventricular assist device as a bridging 
therapy in children who were on waiting lists for 
orthotopic heart transplantation. This device is 
available in several sizes, so that its use may be 
feasible in children of various ages. We com-
pared outcomes in participants who had re-
ceived a ventricular assist device to those in 
propensity-score–matched, historical control 
groups of children who received support with 
ECMO, the only other option for mechanical 
circulatory support that is currently available for 
small children. We found that the rate of sur-
vival to device explantation (owing to either 
transplantation or recovery) was markedly high-
er with the ventricular assist device than with 
ECMO. The outcome comparison was particu-
larly stringent because a successful outcome in 
the ventricular-assist group included an accept-
able neurologic outcome, which could not be 
systematically analyzed in the ECMO group.
As with the use of a ventricular assist device 
for circulatory support in adults, serious adverse 
events, including bleeding, infection, and stroke, 
occurred in a majority of the study participants. 
Although the occurrence of stroke is troubling, 
the stroke rate in this cohort is similar to that 
reported during the use of ventricular assist de-
vices in children who had a body-surface area 
greater than 1.2 m2 and who were treated with 
adult-sized ventricular assist devices.17 The se-
quelae of stroke in this trial did not preclude 
eligibility for transplantation in the majority of 
participants, and the stroke-related deficits were 
generally mild.
An important limitation of this trial is the lack 
of randomization. A randomized design was con-
templated, but equipoise in the medical commu-
nity was lacking. The propensity-score–matching 
process resulted in an ECMO group that was 
statistically similar to the ventricular-assist group. 
However, it is plausible that despite propensity-
score matching, the children in the ECMO group 
were in some respects more ill than those in the 
ventricular-assist group. Given that no other 
mechanical support device exists for these pa-
tients, we believe that children receiving sup-
port with ECMO represent the best comparison 
group.
In conclusion, we found that a ventricular as-
sist device available in several sizes for use in 
children as a bridge to heart transplantation was 
associated with a significantly higher rate of 
survival, as compared with ECMO. Serious ad-
verse events, including infection, stroke, and 
bleeding, occurred in a majority of the study 
participants.
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